Johnson & Johnson (JNJ) DIvidends Date & History

Key Takeaways

• Johnson & Johnson (JNJ) has raised its dividend for 64 consecutive years, placing it among the elite group of Dividend Kings — companies with at least 50 years of uninterrupted dividend increases.
• The current quarterly dividend stands at $1.34 per share, translating to an annualized dividend of roughly $5.36 per share and a dividend yield of approximately 2.07% as of mid-2026.
• The dividend payout ratio is estimated between 46% and 60% of trailing earnings, a level widely considered manageable and sustainable for a mature healthcare giant.
• Free cash flow (FCF) coverage remains strong — in 2025, operating cash flow of $24.53 billion covered the annual dividend obligation of $12.38 billion nearly 2 times over.
• With a beta of approximately 0.22, JNJ offers income-oriented investors a rare combination of low volatility, reliable dividend growth, and defensive sector exposure.

Dividend Overview

Johnson & Johnson (JNJ), the New Brunswick, New Jersey-based healthcare conglomerate, operates across two primary segments: Innovative Medicine and MedTech. The company pays a quarterly dividend of $1.34 per share, amounting to an annualized payout of $5.36. At current share price levels, the dividend yield sits around 2.07%, which is meaningfully above the broader healthcare sector average of approximately 1.45%. JNJ is not a high-yield stock in the traditional sense — investors seeking yields above 4% will not find that here — but it is widely regarded as one of the most consistent and reliable dividend growth stocks in the world. Dividends are paid quarterly, with the most recent ex-dividend date occurring on May 26, 2026, and the corresponding payment made on June 9, 2026. The next quarterly declaration is expected in July 2026.

Dividend History and Growth

Johnson & Johnson's dividend track record is among the most impressive in corporate America. The company has increased its annual dividend for 64 consecutive years, a feat matched by only a handful of publicly traded companies. This streak earned JNJ the designation of Dividend King — reserved for companies that have raised payouts for at least 50 straight years. Over the past decade, the dividend per share has grown at a compound annual growth rate (CAGR) of approximately 5.3%. The most recent increase came in April 2026, when the board authorized a 3.1% raise, lifting the quarterly payout from $1.30 to $1.34 per share. The previous year's increase was 4.8%. Annual dividend growth has generally ranged between 4% and 7% over the last ten years, reflecting a disciplined approach that balances shareholder returns with reinvestment in research and development (R&D) and strategic acquisitions. There have been no dividend cuts during this 64-year period.

Dividend Sustainability and Payout Ratio

The sustainability of JNJ's dividend rests on a solid financial foundation. The payout ratio — the proportion of earnings distributed as dividends — stands between approximately 46% and 60%, depending on whether one uses trailing twelve-month (TTM) GAAP earnings or adjusted earnings per share (EPS). On a GAAP basis, with TTM EPS of roughly $10.73 and an annual dividend of $5.36, the payout ratio is near 50%. A payout ratio below 60% is generally viewed as conservative and leaves ample room for dividend growth, reinvestment, and unforeseen headwinds. Free cash flow coverage further reinforces the dividend's safety. In 2025, JNJ generated $24.53 billion in operating cash flow and approximately $19.70 billion in free cash flow after capital expenditures. Against a total dividend outlay of $12.38 billion, the dividend was covered roughly 1.98 times by operating cash flow. The company's balance sheet remains robust, supported by diversified revenue streams across pharmaceuticals and medical devices, with 28 platforms generating over $1 billion each in annual sales. While looming talc litigation settlements and Medicare price negotiations under the Inflation Reduction Act present financial risks, the dividend itself appears well-protected by JNJ's cash generation capacity.

Dividend Compared to Industry Peers

Within the large-cap pharmaceuticals and healthcare peer group, JNJ's dividend yield of approximately 2.07% sits near the middle of the pack. For context, Pfizer (PFE) has historically offered a higher yield — often above 5% — but with less consistent earnings visibility. Merck (MRK) yields roughly in the 2.5% to 3.0% range, while AbbVie (ABBV) tends to yield between 3% and 4%. The broader healthcare sector average dividend yield is approximately 1.45%, meaning JNJ's yield is comfortably above the sector median. What sets JNJ apart is not the size of the yield but the longevity and consistency of its dividend growth. Few rivals can claim a 64-year growth streak. Additionally, JNJ's beta of 0.22 — among the lowest in the sector — means the stock exhibits far less price volatility than peers, making its dividend returns less susceptible to market turbulence. For investors who prioritize dividend reliability over maximum current yield, JNJ remains a benchmark holding.

AI Screener

For investors looking to identify dividend-paying stocks like Johnson & Johnson or uncover new income-generating opportunities, Tickeron's AI Screener offers a powerful, AI-driven stock and ETF discovery tool. The platform allows users to filter thousands of securities using customizable criteria — including industry, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated trading signals. Dividend-focused investors can screen for stocks based on yield ranges, payout consistency, and fundamental strength, while also scanning for breakout candidates or trend-following setups. By automating the screening process with artificial intelligence, the tool helps traders and investors cut through market noise and identify relevant opportunities far more efficiently than traditional manual research. Explore the AI Screener to see how AI-powered filtering can enhance your investment discovery workflow.

Is This Stock Attractive for Dividend Investors?

Johnson & Johnson is best suited for conservative, long-term dividend growth investors who prioritize reliability and capital preservation over maximum current income. With a 64-year dividend growth streak, a manageable payout ratio, strong free cash flow coverage, and an exceptionally low beta of 0.22, JNJ appeals to retirees and income-oriented portfolios seeking steady, inflation-beating dividend growth with minimal volatility. The stock may be less attractive to yield-maximizing investors, given its roughly 2% yield, or to those seeking rapid dividend growth in the high single digits or above. However, for buy-and-hold investors who value a proven track record of returning capital to shareholders through all economic cycles — including recessions, patent cliffs, and litigation headwinds — JNJ represents one of the most dependable dividend payers in the global equity market. The diversified healthcare business model, spanning pharmaceuticals and medical technology, provides multiple layers of revenue resilience that support the dividend across market environments. While no dividend is guaranteed, JNJ's combination of history, cash flow, and conservative financial management makes it a core holding in many dividend-focused portfolios.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations